Indications1
Indolent Systemic Mastocytosis (ISM)
AYVAKYT is indicated for the treatment of adult patients with indolent systemic mastocytosis (ISM) with moderate to severe symptoms inadequately controlled on symptomatic treatment
Advanced Systemic Mastocytosis (Advanced SM)
AYVAKYT® (avapritinib) is indicated as monotherapy for the treatment of adult patients with aggressive SM (ASM), SM with an associated haematological neoplasm (SM-AHN) or mast cell leukaemia (MCL), after at least one systemic therapy
AYVAKYT is a potent and highly selective inhibitor of KIT D816V1
Adapted from Gilreath JA, et al. 2019.4
Mechanism of disease
Both ISM2,3 and Advanced SM3,4 are driven by KIT D816V mutation in ~95% of cases
Targeted mechanism of action
- AYVAKYT is a tyrosine kinase inhibitor that potently and selectively inhibits the autophosphorylation of KIT D816V, with an IC50 of 0.27 nM in in-vitro biochemical assays1,5
- AYVAKYT inhibits constitutive KIT activation4
- AYVAKYT inhibits mast cell proliferation and activation4
